Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.